摘要
目的探讨贝伐珠单抗与紫杉醇脂质体方案联合治疗晚期胃癌的效果。方法选取98例晚期胃癌患者作为研究对象,按照随机数字表法分为对照组及研究组,各49例。对照组采用紫杉醇脂质体与地西他滨联合化疗治疗,研究组在对照组基础上应用贝伐珠单抗治疗。比较两组临床疗效、血清生长因子[胰岛素样生长因子-1(IGF-1)、转化生长因子-β_(1)(TGF-β_(1))、血管内皮生长因子(VEGF)]水平、生活质量评估量表(QLQ-52)评分与不良反应发生情况。结果研究组总有效率65.31%高于对照组的44.90%(P<0.05)。治疗前两组IGF-1、TGF-β_(1)、VEGF水平比较未见差异性(P>0.05);治疗后研究组IGF-1(82.65±5.23)ng/ml、TGF-β_(1)(22.45±4.02)ng/ml、VEGF(92.45±10.25)ng/L较对照组的(90.56±5.03)ng/ml、(28.95±4.47)ng/ml、(104.52±11.57)ng/L低(P<0.05)。治疗前两组QLQ-52评分比较,结果未见差异性(P>0.05);治疗后研究组QLQ-52评分(70.52±10.23)分较对照组的(62.84±8.45)分高(P<0.05)。两组胃肠道反应、骨髓抑制、肝功能损害、周围神经毒性发生率比较,结果未见差异性(P>0.05)。结论贝伐珠单抗与紫杉醇脂质体方案联合治疗晚期胃癌效果确切,可以有效抑制血清生长因子,改善患者的生活质量,具有临床推广价值。
Objective To explore the effect of bevacizumab combined with paclitaxel liposome in the treatment of advanced gastric cancer.Methods A total of 98 patients with advanced gastric cancer were selected as the study subjects and divided into a control group and a study group according to random number table method,with 49 cases in each group.The control group was treated with combined chemotherapy of paclitaxel liposome and decitabine,and the study group was treated with bevacizumab based on the control group.Both groups were compared in terms of clinical efficacy,serum growth factors[insulin like growth factor-1(IGF-1)and transforming growth factor-β_(1)(TGF-β_(1)),vascular endothelial growth factor(VEGF)]levels,quality of life questionnaire(QLQ-52)score,and the occurrence of adverse reactions.Results The total effective rate of the study group was 65.31%,which was higher than 44.90%of the control group(P<0.05).Before treatment,there were no differences in IGF-1,TGF-β_(1)and VEGF levels between the two groups(P>0.05).After treatment,the study group had IGF-1 of(82.65±5.23)ng/ml,TGF-β_(1)of(22.45±4.02)ng/ml and VEGF of(92.45±10.25)ng/L,which were significantly lower than(90.56±5.03)ng/ml,(28.95±4.47)ng/ml and(104.52±11.57)ng/L in the control group(P<0.05).Before treatment,there was no difference in QLQ-52 score between the two groups(P>0.05).After treatment,the QLQ-52 score of the study group was(70.52±10.23)points,which was higher than(62.84±8.45)points of the control group(P<0.05).There was no difference in the incidence of gastrointestinal reaction,myelosuppression,liver function damage and peripheral nerve toxicity between the two groups(P>0.05).Conclusion The combination of bevacizumab and paclitaxel liposome in the treatment of advanced gastric cancer is effective,which can effectively inhibit serum growth factor,improve the quality of life of patients,and has clinical popularization value.
作者
王传水
WANG Chuan-shui(Shanghe County People's Hospital,Jinan 251600,China)
出处
《中国实用医药》
2024年第8期118-121,共4页
China Practical Medicine
